Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$3.29M$3.29M−70.8% vs Q2 2020 Net Income-$15.50M-$15.50MN/M vs Q2 2020 EPS Diluted-$0.25-$0.25N/M vs Q2 2020 Operating Income-$16,761,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$29,677,000N/M Margins · derivedOperating margin-510.2%−468.8 pt vs Q2 2020
Net margin-471.8%−427.8 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end